Araceli Biosciences Inc. — SEC Form D Filing
Araceli Biosciences Inc. filed an SEC Form D on November 3, 2026, reporting $2.53M raised in Other Technology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- November 3, 2026
- Amount reported
- $2.53M
- Round stage
- Seed stage, as indicated by a $2.5M debt financing round used to scale early platform commercialization and customer deployment.
- Industry
- Other Technology
- Website
- https://aracelibio.com
What the company does
Securities: Debt. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Traditional biological imaging tools process high-density microplates slowly, creating a severe data bottleneck for high-throughput drug discovery.
Solution
Araceli Biosciences builds high-speed cellular imaging hardware and real-time AI analysis software that can image a 1,536-well plate in under four minutes.
Why now
The rapid convergence of automated robotics and AI-driven biological modeling requires unprecedented volumes of high-quality cellular data generated at extreme speed.
Source: SEC EDGAR Form D filing